Evolution of the Average Target: Novartis AG

Data source: Novartis AG(NOVN)

Evolution of the Target Price: Novartis AG

Data source: Novartis AG(NOVN)

Changes in Analyst Recommendations: Novartis AG

Data source: Novartis AG(NOVN)
cdc68d4d0cfe.i4XWDu1KB6Epr3J12VkGvLGIN7gdJnORZRHxavV9-Xg.2PW7fJ8jSuRjwxEknzsx_pzLXvV3TUHXKnK1AIVOqDTf35133DxjyXnAEQ~04244b518af3b526ce69c8e0b2f4e7c7
07:37am Novartis: Incorporating the recent setbacks Alphavalue
07:28am Berenberg Lowers Price Target on Novartis to $130 From $147, Keeps Hold Rating MT
07:28am Berenberg Cuts Novartis Price Target After Recent Pipeline Misses; Hold Rating Kept MT
05:11am Novartis AG : Gets a Neutral rating from Berenberg ZD
09-10 HSBC Upgrades Novartis to Hold From Reduce, Adjusts Price Target to $136 From $123 MT
09-09 Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says MT
09-09 RBC Capital Markets Kicks Off Novartis Coverage at Sector Perform MT
09-09 AlphaValue/Baader Europe Upgrades Novartis to Add, Trims PT MT
09-09 RBC Initiates Novartis at Sector Perform With CHF120 Price Target MT
09-09 Novartis AG : Deutsche Bank gives a Neutral rating ZD
09-09 RBC Kicks Off Novartis Coverage at Sector Perform as Pipeline Misses 'Dampened Momentum' MT
09-08 Novartis AG : RBC gives a Neutral rating ZD
09-08 Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says MT
09-08 Novartis: R&D setbacks are not palatable at premium valuations Alphavalue
09-08 BofA Sees Remibrutinib Detailed Data as Next Major Catalyst to Offset Novartis Pipeline Misses; Buy Rating Kept MT
09-08 Novartis AG : Deutsche Bank remains a Sell rating ZD
09-08 Novartis AG : Jefferies is Neutral ZD
09-08 Novartis AG : Barclays sticks Neutral ZD
09-07 BofA Sees Trial Success of Novartis' Muscular Dystrophy Drug as 'Must-have' After Pelacarsen Miss MT
09-07 Novartis AG : Jefferies sticks Neutral ZD
09-04 Novartis AG : Jefferies is Neutral ZD
09-03 Wall Street's Triple Squeeze Zonebourse
09-02 Novartis AG : Deutsche Bank gives a Buy rating ZD
09-01 BofA Notes Novartis' Positive Data from Remibrutinib Late-stage Trials MT
09-01 Novartis AG : UBS reiterates its Neutral rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+17.42%
+4.34%
+8.75%
+8.17%
+11.56%
+33.47%
+1.45%
+8.34%
+9.21%
Average +11.41%
Weighted average by Cap. +11.86%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
138.20USD
Average target price
153.39USD
Spread / Average Target
+10.99%
High Price Target
185.78USD
Spread / Highest target
+34.43%
Low Price Target
127.34USD
Spread / Lowest Target
-7.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!